Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/37666
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVogler, Meike-
dc.date.accessioned2016-05-31T11:42:10Z-
dc.date.available2016-05-31T11:42:10Z-
dc.date.issued2014-08-27-
dc.identifier.citationAdvances in Medicine, 2014, 2014: 943648en
dc.identifier.issn2356-6752-
dc.identifier.urihttp://www.hindawi.com/journals/amed/2014/943648/en
dc.identifier.urihttp://hdl.handle.net/2381/37666-
dc.description.abstractDue to their central role in the regulation of apoptosis, the antiapoptotic BCL2-proteins are highly promising targets for the development of novel anticancer treatments. To this end, several strategies have been developed to inhibit BCL2, BCL-XL, BCL-w, and MCL1. While early clinical trials in haematological malignancies demonstrated exciting single-agent activity of BCL2-inhibitors, the response in solid tumours was limited, indicating that, in solid tumours, different strategies have to be developed in order to successfully treat patients with BCL2-inhibitors. In this review, the function of the different antiapoptotic BCL2-proteins and their role in solid tumours will be discussed. In addition, a comprehensive analysis of current small molecules targeting these antiapoptotic BCL2-proteins (e.g., ABT-737, ABT-263, ABT-199, TW-37, sabutoclax, obatoclax, and MIM1) will be provided including a discussion of the results of any clinical trials. This analysis will summarise the potential of BCL2-inhibitors for the treatment of solid tumours and will unravel novel approaches to utilise these inhibitors in clinical applications.en
dc.language.isoenen
dc.publisherHindawi Publishing Corporationen
dc.relation.urihttp://www.ncbi.nlm.nih.gov/pubmed/26556430-
dc.rightsCopyright © 2014 Meike Vogler. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en
dc.titleTargeting BCL2-Proteins for the Treatment of Solid Tumoursen
dc.typeJournal Articleen
dc.identifier.doi10.1155/2014/943648-
dc.identifier.eissn2314-758X-
dc.description.statusPeer-revieweden
dc.description.versionPublisher Versionen
dc.type.subtypeJournal Article;Review-
pubs.organisational-group/Organisationen
pubs.organisational-group/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGYen
pubs.organisational-group/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/MBSP Non-Medical Departmentsen
pubs.organisational-group/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/MBSP Non-Medical Departments/Molecular & Cell Biologyen
Appears in Collections:Published Articles, Dept. of Biochemistry

Files in This Item:
File Description SizeFormat 
Targeting BCL2-Proteins for the Treatment of Solid Tumours..pdfPublished (publisher PDF)718.89 kBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.